Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. EST on January 12, 2021. Management will also participate in one-on-one …

Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices …

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase …

Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020. Mr. Doyle and Dr. Weinberg will take part in a fireside chat at 11:20am EST …

Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting on November 19 through November 21. …

Novocure Receives CE Mark for NovoTTF-100L™ System

The application of CE mark enables Novocure to commercialize the NovoTTF-100L System as a treatment for Malignant Pleural Mesothelioma in the European Union and Switzerland ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that it has received the …

Novocure Announces Agenda for Virtual Research and Development Day

Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EST on Thursday, November 12, 2020. The …

Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks

Provides flexible capital structure prior to anticipated period of significant innovation and growth ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured revolving credit facility with JPMorgan Chase Bank, N.A. …

Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement

Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million aggregate principal amount of its 0% Convertible Senior Notes due 2025 …

Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement

Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% Convertible Senior Notes due 2025 (the “notes”) through a private placement …